Business Secretary Vince Cable recently announced a new scheme to grant UK researchers access to a range of valuable deprioritised pharmaceutical compounds.
This is being led by the Medical Research Council in partnership with seven global pharmaceutical companies: AstraZeneca, GlaxoSmithKline, Janssen Research & Development LLC, Lilly, Pfizer, Takeda and UCB.
This will allow researchers to conduct new studies to improve our understanding of disease, which could in turn lead to more effective treatments.
The compounds have all undergone some industry development but were not effective enough against the target disease. However, they could be used to fight other diseases with similar pathways.
For more information please see the original article.